NSCLC, metastatic
Invited discussant abstracts 1211PD, 1212PD, 1213PD and 1214PD
Date
09 Oct 2016Session
NSCLC, metastaticPresenters
Ken O'ByrneAuthors
K. O'ByrneAuthor affiliations
- Department Of Medical Oncology, Princess Alexandra Hospital, 4102 - Brisbane/AU
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
2041 - LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)
Presenter: Atsushi Horiike
Session: NSCLC, metastatic
Resources:
Abstract
1608 - Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
Presenter: Vamsidhar Velcheti
Session: NSCLC, metastatic
Resources:
Abstract
1911 - Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study
Presenter: Sun Min Lim
Session: NSCLC, metastatic
Resources:
Abstract
2435 - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001
Presenter: Alice Shaw
Session: NSCLC, metastatic
Resources:
Abstract
Invited discussant abstracts 1203PD, 1204PD, 1205PD and 1206PD
Presenter: Enriqueta Felip
Session: NSCLC, metastatic
Resources:
Slides
Webcast
1753 - Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
Presenter: Lyudmila Bazhenova
Session: NSCLC, metastatic
Resources:
Abstract
2387 - Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Presenter: Leena Gandhi
Session: NSCLC, metastatic
Resources:
Abstract
3636 - Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Presenter: Leora Horn
Session: NSCLC, metastatic
Resources:
Abstract
Invited discussant abstracts 1207PD, 1209PD and 1210PD
Presenter: Sanjay Popat
Session: NSCLC, metastatic
Resources:
Slides
Webcast
3933 - Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC): the French IFCT-PREDICT.amm study
Presenter: A Drezet
Session: NSCLC, metastatic
Resources:
Abstract